相关实验视频

Updated: Jan 14, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

患者对复发/耐药性扩散型大B细胞淋巴瘤双特异性抗体属性的偏好在美国

Erin Mulvey¹, Jason Shafrin², Kyi-Sin Than³

¹Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

Future oncology (London, England)

|October 21, 2025

概括

在扩散性大B细胞淋巴瘤 (DLBCL) 中,患者对双特异性抗体的偏好优先考虑安全性和疗效,而不是给药途径. 患者重视减少细胞因子释放综合征 (CRS) 和改善的生存率,影响治疗持续时间的选择.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床药理学临床药理学

背景情况:

两种新型双特异性抗体 (bsAbs),即epcoritamab (皮下,SC) 和glofitamab (静脉注射,IV),已被批准用于复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL).
埃普科里塔马布 (epcoritamab) 给予直到进展 (TTP),而格洛菲塔马布 (glofitamab) 则给予固定的持续时间 (FTD).
了解患者的偏好对于在DLBCL治疗选择中共享决策至关重要.

研究的目的:

评估患者对扩散型大B细胞淋巴瘤 (DLBCL) 中双特异性抗体 (bsAbs) 关键属性的偏好.
为了确定患者对bsAbs治疗的决策中最有影响的因素.
为了在临床讨论中为DLBCL患者选择合适的bsAbs提供信息.

主要方法:

对123名DLBCL患者进行了一项离散选择实验.
患者根据总生存 (OS),完全响应 (CR) 率,细胞因子释放综合征 (CRS) 的风险和住院治疗,治疗持续时间 (FTD vs. TTP) 和施用途径 (SC vs. IV) 评估了bsAbs.
使用条件后勤回归来估计每个属性的偏好权重.

主要成果:

细胞因子释放综合征 (CRS) 和与CRS相关的住院治疗是患者偏好的最重要的驱动因素.
总体存活率 (OS) 和完整响应 (CR) 也被高度评价,其次是治疗持续时间.
虽然患者通常更喜欢固定持续时间 (FTD) 治疗,但他们更喜欢直到进展 (TTP),如果它提供了减少的CRS或改善的生存结果. 给药途径 (SC与IV) 对偏好的影响最小.

结论:

有效性 (OS,CR) 和安全性 (CRS风险,住院) 在DLBCL患者对bsAbs.的偏好中至关重要.
患者愿意考虑TTP而不是FTD,如果它提高了疗效或安全性,突出了生活质量的重要性.
这些发现支持以患者为中心的讨论,以优化DLBCL管理中的bsAbs选择.

关键词:

双特异性抗体双特异性抗体 DLBCL DLBCL 是一个字母.分散的选择选择的选择.淋巴瘤淋巴瘤是什么患者的偏好,患者的偏好.调查调查调查调查调查调查调查调查

更多相关视频

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...